By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Orexigen Therapeutics, Inc. 

48 Wall Street
Suite 1100
New York  New York  10005  U.S.A.
Phone: 212-918-4650 Fax: 212-918-4801



Company News
Orexigen (OREX) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 6/23/2016 6:22:54 AM
San Diego's Orexigen (OREX) Names a New CFO and COO 6/9/2016 5:56:34 AM
Orexigen (OREX) Reports Favorable Markman Ruling In Contrave Patent Litigation 6/8/2016 7:54:52 AM
Orexigen (OREX) Founder And Former Chairman Eckard Weber Steps Down From Board 5/27/2016 9:57:17 AM
Orexigen (OREX) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 5/26/2016 7:19:31 AM
Orexigen (OREX) Appoints New Member Of Board Of Directors And Announces Senior Management Changes 5/23/2016 6:42:09 AM
Orexigen (OREX) Reports Business And Financial Results For The First Quarter Ended March 31, 2016 5/5/2016 6:50:45 AM
Orexigen (OREX) To Speak At The Bank of America (BAC) Merrill Lynch 2016 Health Care Conference 5/4/2016 8:02:28 AM
Orexigen (OREX) Expands Commercial Leadership Team With Appointment Of Healthcare Industry Veteran Brian Longstreet As Senior Vice President Of Global Market Access And Development 5/3/2016 6:53:32 AM
Orexigen (OREX) Announces South Korean Approval Of Contrave (Naltrexone HCI And Bupropion HCI Extended-Release) Monotherapy For Weight Management In Overweight Or Obese Adult Patients 5/2/2016 6:47:37 AM